Ontology highlight
ABSTRACT:
SUBMITTER: Walker EC
PROVIDER: S-EPMC2810087 | biostudies-other | 2010 Feb
REPOSITORIES: biostudies-other
Walker Emma C EC McGregor Narelle E NE Poulton Ingrid J IJ Solano Melissa M Pompolo Sueli S Fernandes Tania J TJ Constable Matthew J MJ Nicholson Geoff C GC Zhang Jian-Guo JG Nicola Nicos A NA Gillespie Matthew T MT Martin T John TJ Sims Natalie A NA
The Journal of clinical investigation 20100104 2
Effective osteoporosis therapy requires agents that increase the amount and/or quality of bone. Any modification of osteoclast-mediated bone resorption by disease or drug treatment, however, elicits a parallel change in osteoblast-mediated bone formation because the processes are tightly coupled. Anabolic approaches now focus on uncoupling osteoblast action from osteoclast formation, for example, by inhibiting sclerostin, an inhibitor of bone formation that does not influence osteoclast differen ...[more]